Gardasil 9 HPV vaccine receives FDA approval for use in males 16-26 for the prevention of anal cancer
by Staff from Outbreak News Today on (#Y6C0)
Merck announced this week that the U.S. Food and Drug Administration (FDA) approved an expanded age indication for GARDASIL(R)9 (Human Papillomavirus 9-valent Vaccine, Recombinant), Merck's 9-valent human papillomavirus (HPV) vaccine, to now include use in males 16 through 26 years of age, for the prevention of anal cancer caused by HPV types 16, 18, 31, 33, 45, ["]
